PFE.N
Latest Trade
40.79USDChange
1.38(+3.50%)Volume
7,661,230Today's Range
-
41.4152 Week Range
-
41.99As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 39.41 |
|---|---|
Open | 40.49 |
Volume | 7,661,230 |
3M AVG Volume | 689.42 |
Today's High | 41.41 |
Today's Low | 40.31 |
52 Week High | 41.99 |
52 Week Low | 27.89 |
Shares Out (MIL) | 5,559.96 |
Market Cap (MIL) | 213,002.20 |
Forward P/E | 13.64 |
Dividend (Yield %) | 3.97 |
UK Authorizes Pfizer-Biontech COVID-19 Vaccine
Pfizer Says Co & Biontech Achieve First Authorization In World For A Vaccine To Combat Covid-19
Biontech And Pfizer Achieve Authorization For COVID-19 Vaccine
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.
Industry
Biotechnology & Drugs
Executive Leadership
Albert Bourla
Chairman of the Board, Chief Executive Officer
John D. Young
Chief Business Officer, Group President
Frank A. D'Amelio
Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Angela Hwang
Group President, Pfizer Biopharmaceuticals Group
Dawn Rogers
Chief Human Resource Officer, Executive Vice President
Price To Earnings (TTM) | 25.75 |
|---|---|
Price To Sales (TTM) | 4.38 |
Price To Book (MRQ) | 3.26 |
Price To Cash Flow (TTM) | 15.76 |
Total Debt To Equity (MRQ) | 96.77 |
LT Debt To Equity (MRQ) | 76.29 |
Return on Investment (TTM) | 6.05 |
Return on Equity (TTM) | 4.81 |
* EU watchdog urges longer approval process (Adds stock market detail)
* UK is first in Western world to authorise a COVID-19 vaccine
Celebrating Britain's swift approval of BioNtech and Pfizer's coronavirus vaccine as a benefit of Brexit is misplaced since the vaccine was itself a product of the European Union that Britain has left, German Health Minister Jens Spahn said.
* Canadian dollar dips 0.1% against the greenback * The loonie touches its strongest since October 2018 at 1.2916 * Canadian labor productivity falls by a record 10.3% * Canada's 10-year yield touches a near 3-week high at 0.780% TORONTO, Dec 2 (Reuters) - The Canadian dollar...
Britain on Wednesday became the first Western country to approve a COVID-19 vaccine, jumping ahead of the United States and Europe after its regulator cleared a shot developed by Pfizer and BioNTech for emergency use in record time.
Britain leapt ahead of the United States in approving Pfizer's COVID-19 vaccine on Wednesday, intensifying scrutiny on U.S. regulators as they consider whether to grant emergency use in the country that leads the world in coronavirus infections.
Germany has opted for a longer procedure to approve COVID-19 vaccines than the emergency process chosen by Britain for the shot developed by Pfizer and BioNTech, because it wanted to increase confidence in vaccines, the country's health minister said on Wednesday.
Britain’s approval of Pfizer’s COVID-19 vaccine will not have an impact on the number of doses available in Germany, a spokesman for the German health ministry said on Wednesday.
Britain on Wednesday became the first country in the world to approve the COVID-19 vaccine developed by U.S. drugmaker Pfizer and its German partner BioNTech , and said it will be rolled out from early next week.
The frontrunners in the COVID-19 vaccine race have emerged with different success rates for their shots in clinical trials, prompting a scramble across Europe to prepare for the daunting challenge of inoculating 450 million people across almost 30 countries. That race has...
Britain on Wednesday became the first Western country to approve a COVID-19 vaccine, jumping ahead of the United States and Europe after its regulator cleared a shot developed by Pfizer and BioNTech for emergency use in record time.
* For a separate FACTBOX on other vaccines, click , and click for the frontrunners (Adds UK approval, updates regulatory reviews section) Dec 2 (Reuters) - Britain on Wednesday became the first country in the world to approve the Pfizer-BioNTech COVID-19 vaccine for use...
World stocks hovered near record highs on Wednesday on hopes for a coronavirus vaccine and additional U.S. economic stimulus, though enthusiasm for riskier assets left the dollar stuck at a 2-1/2 year low.
Britain's emergency approval of the experimental COVID-19 vaccine being developed by Pfizer and BioNTech is "problematic" as it was done too hastily, a prominent European Union lawmaker said on Wednesday.
London-listed shares were muted on Wednesday as fears about a no-deal Brexit overshadowed news that the UK had become the world's first country to approve the Pfizer-BioNTech COVID-19 vaccine.
European shares slipped on Wednesday as investors took stock following a near 14% rally last month, while shares in BioNTech surged after UK became the first country to approve its COVID-19 vaccine developed with Pfizer.
* Pfizer-BioNTech seek EU emergency approval for COVID-19 vaccine
* Pfizer-BioNTech seek EU emergency approval for COVID-19 vaccine
* Pfizer-BioNTech seek EU emergency approval for COVID-19 vaccine
* Pfizer-BioNTech seek EU emergency approval for COVID-19 vaccine
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.